Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Allogene Therapeutics Inc (ALLO)

Allogene Therapeutics Inc (ALLO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 754,150
  • Shares Outstanding, K 169,092
  • Annual Sales, $ 100 K
  • Annual Income, $ -327,270 K
  • 60-Month Beta 0.81
  • Price/Sales 7,493.45
  • Price/Cash Flow N/A
  • Price/Book 1.40
Trade ALLO with:

Options Overview Details

View History
  • Implied Volatility 99.65% ( -17.51%)
  • Historical Volatility 74.92%
  • IV Percentile 59%
  • IV Rank 21.96%
  • IV High 388.20% on 10/31/23
  • IV Low 18.47% on 11/09/23
  • Put/Call Vol Ratio 0.00
  • Today's Volume 25
  • Volume Avg (30-Day) 89
  • Put/Call OI Ratio 0.12
  • Today's Open Interest 6,268
  • Open Int (30-Day) 7,223

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 18 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.40
  • Number of Estimates 9
  • High Estimate -0.33
  • Low Estimate -0.48
  • Prior Year -0.68
  • Growth Rate Est. (year over year) +41.18%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.12 +8.25%
on 03/19/24
5.78 -22.77%
on 03/08/24
-0.68 (-13.23%)
since 02/27/24
3-Month
2.61 +70.88%
on 01/05/24
5.78 -22.77%
on 03/08/24
+1.26 (+39.38%)
since 12/27/23
52-Week
2.23 +100.00%
on 12/01/23
6.89 -35.27%
on 05/15/23
-0.57 (-11.33%)
since 03/27/23

Most Recent Stories

More News
Allogene Therapeutics: Q4 Earnings Snapshot

Allogene Therapeutics: Q4 Earnings Snapshot

ALLO : 4.46 (+5.94%)
Allogene Therapeutics: Q3 Earnings Snapshot

Allogene Therapeutics: Q3 Earnings Snapshot

ALLO : 4.46 (+5.94%)
A Bull Market Is Coming: 1 Beaten-Down Growth Stock You Could Regret Not Buying on the Dip

Wall Street price targets suggest this stock can rocket more than 400% higher.

CRBU : 5.12 (+1.19%)
ALLO : 4.46 (+5.94%)
GILD : 73.01 (+0.83%)
Cantor Fitzgerald Bolsters Healthcare and Biotechnology Equity Research Team with Addition of Josh Schimmer, M.D., and Eric Schmidt, Ph.D.

/PRNewswire/ -- Cantor Fitzgerald, L.P., ("Cantor") a leading global financial services firm, today announced the addition of Josh Schimmer, M.D., and Eric...

ALLO : 4.46 (+5.94%)
Allogene Therapeutics: Q2 Earnings Snapshot

Allogene Therapeutics: Q2 Earnings Snapshot

ALLO : 4.46 (+5.94%)
3 Stocks With Sky-High Short Interest Levels

BYND, BTAI, and ALLO stand out as high short-interest stocks to watch due to their potential for price fluctuations and short-squeeze opportunities.

BTAI : 2.88 (+0.70%)
BYND : 8.29 (+0.85%)
ALLO : 4.46 (+5.94%)
CVNA : 90.31 (-0.55%)
RIVN : 10.99 (+4.47%)
ENVX : 8.03 (+5.24%)
Reata (RETA) Q1 Earnings Miss, Stock Dips on Pipeline Updates

Reata (RETA) incurs wider-than-expected loss in the first quarter. The company discontinues the development of bardoxolone methyl for diabetic kidney disease.

RETA : 172.36 (+0.02%)
RCUS : 18.21 (+9.37%)
ALLO : 4.46 (+5.94%)
OCUP : 2.02 (-0.49%)
TEVA Q1 Earnings Miss Estimates, Sales Beat, Stock Declines

TEVA reports mixed Q1 results, missing earnings estimates but beating the same for revenues. Stock falls.

TEVA : 14.43 (+2.05%)
RCUS : 18.21 (+9.37%)
ALLO : 4.46 (+5.94%)
OCUP : 2.02 (-0.49%)
Amicus (FOLD) Q1 Earnings Miss, Galafold Sales Grow

Amicus (FOLD) incurs wider-than-expected loss in the first quarter. Revenues, however, beat estimates. The company reiterates its 2023 guidance.

FOLD : 11.86 (+3.76%)
RCUS : 18.21 (+9.37%)
ALLO : 4.46 (+5.94%)
OCUP : 2.02 (-0.49%)
Iovance (IOVA) Posts Narrower-Than-Expected Loss in Q1

Iovance (IOVA) reports Q1 earnings that beat our estimates. The company's acquisition of IL-2 product Proleukin is expected to close in second-quarter 2023.

MRK : 131.75 (+4.96%)
IOVA : 14.10 (+0.36%)
ALLO : 4.46 (+5.94%)
ATHA : 2.56 (-1.16%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Strengthening short term outlook on maintaining the current direction.

See More Share

Business Summary

Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company, primarily focused on the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer.'

See More

Key Turning Points

3rd Resistance Point 5.17
2nd Resistance Point 4.90
1st Resistance Point 4.68
Last Price 4.46
1st Support Level 4.19
2nd Support Level 3.92
3rd Support Level 3.70

See More

52-Week High 6.89
Fibonacci 61.8% 5.11
Fibonacci 50% 4.56
Last Price 4.46
Fibonacci 38.2% 4.01
52-Week Low 2.23

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar